Danish biotechnology company Evaxion announced preclinical results showing that its multi-component Cytomegalovirus vaccine candidate, developed using an Artificial Intelligence immunology platform, successfully controlled infection in preclinical studies, advancing efforts to develop a vaccine against a virus that currently has no approved preventive treatment and can cause severe congenital disabilities.